DDInter108 DDInter899
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Apixaban {u} (Compound) binds {v} (Gene) CYP2C8
Apixaban {u} (Compound) causes {v} (Side Effect) Incision site haemorrhage
Apixaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Apixaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duloxetine
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Apixaban {u} may lead to a major life threatening interaction when taken with {v} Desirudin
Apixaban {u} may lead to a major life threatening interaction when taken with {v} Trastuzumab emtansine
Apixaban (Compound) binds CYP2C8 (Gene)
Apixaban (Compound) causes Incision site haemorrhage (Side Effect)
Apixaban may cause a minor interaction that can limit clinical effects when taken with Capsicum
Apixaban may cause a minor interaction that can limit clinical effects when taken with Modafinil
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Apixaban may lead to a major life threatening interaction when taken with Desirudin
Apixaban may lead to a major life threatening interaction when taken with Trastuzumab emtansine